NR1H4 and primary biliary cholangitis: Finally, in the INTREPID study, 68 patients with PBC were randomized to 12-week treatment with EDP-305, a potent non-bile acid FXR agonist, which has been shown to suppress liver injury and fibrosis in animal models.